[Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004135
German
Original Title:
Nivolumab (Urothelkarzinom, adjuvant) - Nutzenbewertung gemäß § 35a SGB V
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-53.html
Year Published:
2022
URL for published report:
https://www.iqwig.de/download/a22-53_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Carcinoma, Transitional Cell
- Nivolumab
- Antibodies, Monoclonal, Humanized
- Urinary Bladder Neoplasms
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Keywords
- Nivolumab
- Carcinoma - Transitional Cell
- Benefit Assessment
- NCT02632409
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.